Bioventus expands hyaluronic acid product for osteoarthritis into Australia, New Zealand

Biologics

Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand.

Four things to know:

1. Durolane is used in the symptomatic treatment of mild to moderate hip osteoarthritis and mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes.

2. The orthobiologic company is also launching another HA-based product, Durolane SJ, in both countries later this year.

3. Durolane SJ is used in the symptomatic treatment of mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes.

4. Both products are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the operation.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

 

Featured Webinars

Featured Whitepapers